You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEtoricoxib
Accession NumberDB01628  (DB07166)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionEtoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid.
Structure
Thumb
Synonyms
5-chloro-2-(6-Methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine
5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl
5-chloro-6'-Methyl-3-(P-(methylsulfonyl)phenyl)-2,3'-bipyridine
ETORICOXIB
Etoricoxibum
L791456
External Identifiers
  • MK-663
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlgixNot Available
ArcoxiaNot Available
CoxyveenSolmarc Lifesciences
EtorixNot Available
NucoxiaNot Available
TauxibNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIWRX4NFY03R
CAS number202409-33-4
WeightAverage: 358.842
Monoisotopic: 358.054276131
Chemical FormulaC18H15ClN2O2S
InChI KeyMNJVRJDLRVPLFE-UHFFFAOYSA-N
InChI
InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
IUPAC Name
5-chloro-3-(4-methanesulfonylphenyl)-2-(6-methylpyridin-3-yl)pyridine
SMILES
CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O
Pharmacology
IndicationFor the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
Structured Indications Not Available
PharmacodynamicsEtoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1). Currently it is approved in more than 60 countries worldwide but not in the US, where the Food and Drug Administration (FDA) require additional safety and efficacy data for etoricoxib before it will issue approval.
Mechanism of actionLike any other COX-2 selective inhibitor Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces prostaglandins (PGs) generation from arachidonic acid.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Related Articles
AbsorptionBioavailability is 100% following oral administration.
Volume of distributionNot Available
Protein binding92%
Metabolism

Hepatic, primarily via CYP3A4.

SubstrateEnzymesProduct
Etoricoxib
Etoricoxib 1'-N'-oxideDetails
Etoricoxib
6-HydroxymethyletoricoxibDetails
6-Hydroxymethyletoricoxib
6-Hydroxymethyletoricoxib 1'-N'-oxideDetails
6-Hydroxymethyletoricoxib
6-Carboxy-etoricoxibDetails
6-Hydroxymethyletoricoxib
6-Hydroxymethyletoricoxib glucuronideDetails
Route of eliminationNot Available
Half life22 hours
ClearanceNot Available
ToxicityThis reduced activity is the cause of reduced gastrointestinal toxicity, as demonstrated in several large clinical trials performed with different COXIB (see below links on NEJM and The Lancet). Some clinical trials and meta-analysis showed that treatment with COXIB lead to increased incidence of cardiovascular adverse events compared to placebo
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Etoricoxib Action PathwayDrug actionSMP00695
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with 5-androstenedione.Experimental, Illicit
AbciximabEtoricoxib may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Etoricoxib can be increased when it is combined with Abiraterone.Approved
AcebutololEtoricoxib may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Etoricoxib.Approved
AcenocoumarolEtoricoxib may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Etoricoxib.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etoricoxib.Approved, Vet Approved
AclarubicinEtoricoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Etoricoxib.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Alendronic acid.Approved
AliskirenEtoricoxib may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololEtoricoxib may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Etoricoxib.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Amcinonide.Approved
AmikacinEtoricoxib may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideEtoricoxib may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Etoricoxib can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinEtoricoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodEtoricoxib may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Etoricoxib.Investigational
annamycinEtoricoxib may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etoricoxib.Approved
Antithrombin III humanEtoricoxib may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Etoricoxib may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanEtoricoxib may increase the anticoagulant activities of Apixaban.Approved
ApramycinEtoricoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Etoricoxib.Approved, Investigational
AprepitantThe serum concentration of Etoricoxib can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinEtoricoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinEtoricoxib may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanEtoricoxib may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololEtoricoxib may decrease the antihypertensive activities of Arotinolol.Approved
ArtemetherThe metabolism of Etoricoxib can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Etoricoxib can be decreased when combined with Atazanavir.Approved, Investigational
AtenololEtoricoxib may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Etoricoxib can be decreased when combined with Atomoxetine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etoricoxib.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Etoricoxib.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etoricoxib.Approved
AzithromycinThe metabolism of Etoricoxib can be decreased when combined with Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Etoricoxib.Approved, Investigational
BazedoxifeneEtoricoxib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminEtoricoxib may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololEtoricoxib may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Etoricoxib.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etoricoxib.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Etoricoxib.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etoricoxib.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Betamethasone.Approved, Vet Approved
BetaxololThe metabolism of Etoricoxib can be decreased when combined with Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Etoricoxib.Investigational
BevantololEtoricoxib may decrease the antihypertensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Etoricoxib can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
BisoprololEtoricoxib may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinEtoricoxib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Etoricoxib can be decreased when combined with Boceprevir.Approved
BopindololEtoricoxib may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Etoricoxib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Etoricoxib can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etoricoxib.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Etoricoxib.Investigational
BucindololEtoricoxib may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Budesonide.Approved
BufuralolEtoricoxib may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideEtoricoxib may decrease the diuretic activities of Bumetanide.Approved
BupranololEtoricoxib may decrease the antihypertensive activities of Bupranolol.Approved
BupropionThe metabolism of Etoricoxib can be decreased when combined with Bupropion.Approved
CaffeineThe metabolism of Etoricoxib can be decreased when combined with Caffeine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Etoricoxib.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etoricoxib.Experimental
CapecitabineThe metabolism of Etoricoxib can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Etoricoxib.Approved
CarbamazepineThe metabolism of Etoricoxib can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etoricoxib.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Etoricoxib.Approved, Vet Approved, Withdrawn
CarteololEtoricoxib may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolEtoricoxib may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Etoricoxib.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etoricoxib.Approved, Investigational
CeliprololEtoricoxib may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Etoricoxib can be increased when it is combined with Ceritinib.Approved
CertoparinEtoricoxib may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etoricoxib.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etoricoxib.Approved, Vet Approved
ChlorotrianiseneEtoricoxib may increase the thrombogenic activities of Chlorotrianisene.Withdrawn
ChlorpromazineThe metabolism of Etoricoxib can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etoricoxib.Approved
CholecalciferolThe metabolism of Etoricoxib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etoricoxib.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Etoricoxib.Approved
CimetidineThe metabolism of Etoricoxib can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Etoricoxib can be decreased when combined with Cinacalcet.Approved
CinoxacinEtoricoxib may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinEtoricoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Etoricoxib.Approved
Citric AcidEtoricoxib may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Etoricoxib can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Etoricoxib can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Etoricoxib can be decreased when combined with Clobazam.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clodronate.Approved, Investigational, Vet Approved
ClomipramineThe metabolism of Etoricoxib can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Etoricoxib.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Etoricoxib.Vet Approved
ClotrimazoleThe metabolism of Etoricoxib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Etoricoxib can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Etoricoxib can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Etoricoxib can be decreased when combined with Cocaine.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Etoricoxib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensEtoricoxib may increase the thrombogenic activities of Conjugated Equine Estrogens.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Etoricoxib can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Etoricoxib.Investigational
CyclosporineEtoricoxib may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Etoricoxib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Etoricoxib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Etoricoxib.Investigational
Dabigatran etexilateEtoricoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Etoricoxib can be decreased when it is combined with Dabrafenib.Approved
DalteparinEtoricoxib may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEtoricoxib may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Etoricoxib.Investigational
DarifenacinThe metabolism of Etoricoxib can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Etoricoxib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Etoricoxib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinEtoricoxib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Etoricoxib can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Etoricoxib can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Etoricoxib can be decreased when combined with Desipramine.Approved
DesirudinEtoricoxib may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Etoricoxib.Approved
DexamethasoneThe serum concentration of Etoricoxib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Etoricoxib.Approved
DextranEtoricoxib may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Etoricoxib may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Etoricoxib may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Etoricoxib may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Etoricoxib.Approved, Vet Approved
DicoumarolEtoricoxib may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolEtoricoxib may increase the thrombogenic activities of Dienestrol.Approved
DiethylstilbestrolEtoricoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etoricoxib.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Etoricoxib.Approved
DihydroergotamineThe metabolism of Etoricoxib can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinEtoricoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemThe metabolism of Etoricoxib can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Etoricoxib.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Etoricoxib.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Etoricoxib.Approved
DiphenhydramineThe metabolism of Etoricoxib can be decreased when combined with Diphenhydramine.Approved
DoxorubicinEtoricoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Etoricoxib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Etoricoxib can be decreased when combined with Dronedarone.Approved
DrospirenoneEtoricoxib may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Etoricoxib.Approved
DuloxetineDuloxetine may increase the antiplatelet activities of Etoricoxib.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Etoricoxib.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Etoricoxib.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Etoricoxib.Investigational
Edetic AcidEtoricoxib may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEtoricoxib may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Etoricoxib can be decreased when it is combined with Efavirenz.Approved, Investigational
EliglustatThe metabolism of Etoricoxib can be decreased when combined with Eliglustat.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Etoricoxib.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Etoricoxib.Approved
EnoxacinEtoricoxib may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinEtoricoxib may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Etoricoxib can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Etoricoxib.Approved
EpirubicinEtoricoxib may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneEtoricoxib may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etoricoxib.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etoricoxib.Approved
EquileninThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Equilin.Approved
ErythromycinThe metabolism of Etoricoxib can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Etoricoxib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololEtoricoxib may decrease the antihypertensive activities of Esmolol.Approved
EstradiolEtoricoxib may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
EstriolEtoricoxib may increase the thrombogenic activities of Estriol.Approved, Vet Approved
EstroneEtoricoxib may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Estrone sulfate.Approved
Etacrynic acidEtoricoxib may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Etoricoxib.Approved, Investigational
Ethinyl EstradiolEtoricoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateEtoricoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Etoricoxib.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Etoricoxib.Approved
EtoperidoneEtoperidone may increase the antiplatelet activities of Etoricoxib.Approved
EtravirineThe serum concentration of Etoricoxib can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Etoricoxib.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Etoricoxib.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Etoricoxib.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etoricoxib.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Etoricoxib.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Etoricoxib.Approved
FleroxacinEtoricoxib may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Etoricoxib.Approved, Withdrawn
FloxuridineThe metabolism of Etoricoxib can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with fluasterone.Investigational
FluconazoleThe metabolism of Etoricoxib can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fludrocortisone.Approved
FluindioneEtoricoxib may increase the anticoagulant activities of Fluindione.Investigational
FlumequineEtoricoxib may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Etoricoxib.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Etoricoxib can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Etoricoxib can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Etoricoxib.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etoricoxib.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Etoricoxib can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Etoricoxib can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Etoricoxib.Approved, Nutraceutical, Vet Approved
FondaparinuxEtoricoxib may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumEtoricoxib may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Etoricoxib.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Etoricoxib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Etoricoxib can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etoricoxib.Approved
FosphenytoinThe metabolism of Etoricoxib can be increased when combined with Fosphenytoin.Approved
FramycetinEtoricoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideEtoricoxib may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Etoricoxib can be increased when it is combined with Fusidic Acid.Approved
GabexateEtoricoxib may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinEtoricoxib may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinEtoricoxib may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Etoricoxib.Approved, Withdrawn
GemfibrozilThe metabolism of Etoricoxib can be decreased when combined with Gemfibrozil.Approved
GemifloxacinEtoricoxib may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinEtoricoxib may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinEtoricoxib may increase the thrombogenic activities of Genistein.Investigational
GentamicinEtoricoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AEtoricoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinEtoricoxib may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Etoricoxib is combined with HE3286.Investigational
HeparinEtoricoxib may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolEtoricoxib may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Etoricoxib.Investigational
HirulogEtoricoxib may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Etoricoxib.Investigational
HydralazineEtoricoxib may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etoricoxib.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etoricoxib.Approved
Hygromycin BEtoricoxib may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Etoricoxib.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Etoricoxib.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Etoricoxib.Approved
IdarubicinEtoricoxib may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Etoricoxib can be increased when it is combined with Idelalisib.Approved
idraparinuxEtoricoxib may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
ImatinibThe metabolism of Etoricoxib can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Etoricoxib.Investigational
ImipramineThe metabolism of Etoricoxib can be decreased when combined with Imipramine.Approved
IndalpineIndalpine may increase the antiplatelet activities of Etoricoxib.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etoricoxib.Approved
IndenololEtoricoxib may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Etoricoxib can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etoricoxib.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Etoricoxib.Withdrawn
INNO-206Etoricoxib may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Etoricoxib can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Etoricoxib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Etoricoxib can be decreased when combined with Isoniazid.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Etoricoxib.Withdrawn
IsradipineThe metabolism of Etoricoxib can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Etoricoxib can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Etoricoxib can be increased when it is combined with Ivacaftor.Approved
KanamycinEtoricoxib may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Etoricoxib.Experimental
KetoconazoleThe metabolism of Etoricoxib can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etoricoxib.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Etoricoxib.Approved
LabetalolEtoricoxib may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Etoricoxib.Approved, Investigational
LepirudinEtoricoxib may increase the anticoagulant activities of Lepirudin.Approved
LevobunololEtoricoxib may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinEtoricoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Etoricoxib.Approved
LidocaineThe metabolism of Etoricoxib can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Etoricoxib.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Etoricoxib.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Etoricoxib.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Etoricoxib.Approved
LomefloxacinEtoricoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved
LopinavirThe metabolism of Etoricoxib can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Etoricoxib can be decreased when combined with Lorcaserin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Etoricoxib.Approved
LosartanThe metabolism of Etoricoxib can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Etoricoxib can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Etoricoxib.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Etoricoxib.Approved, Investigational
LuliconazoleThe serum concentration of Etoricoxib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Etoricoxib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Etoricoxib can be decreased when combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Etoricoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Etoricoxib.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etoricoxib.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etoricoxib.Approved
ME-609The risk or severity of adverse effects can be increased when Etoricoxib is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etoricoxib.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etoricoxib.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Etoricoxib.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etoricoxib.Approved
MestranolEtoricoxib may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Etoricoxib.Withdrawn
MethadoneThe metabolism of Etoricoxib can be decreased when combined with Methadone.Approved
MethallenestrilEtoricoxib may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Etoricoxib.Approved
MethotrimeprazineThe metabolism of Etoricoxib can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etoricoxib.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Methylprednisolone.Approved, Vet Approved
MetipranololEtoricoxib may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etoricoxib.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Etoricoxib.Approved, Investigational
MetrizamideEtoricoxib may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MexiletineThe metabolism of Etoricoxib can be decreased when combined with Mexiletine.Approved
MifepristoneThe serum concentration of Etoricoxib can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Etoricoxib.Approved
MirabegronThe metabolism of Etoricoxib can be decreased when combined with Mirabegron.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Etoricoxib.Approved
MitotaneThe serum concentration of Etoricoxib can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Etoricoxib.Investigational
ModafinilThe serum concentration of Etoricoxib can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Etoricoxib.Approved
MometasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Etoricoxib.Approved
MoxifloxacinEtoricoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etoricoxib.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etoricoxib.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etoricoxib.Approved
NadololEtoricoxib may decrease the antihypertensive activities of Nadolol.Approved
NadroparinEtoricoxib may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Etoricoxib.Investigational
NafcillinThe serum concentration of Etoricoxib can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Etoricoxib.Approved
Nalidixic AcidEtoricoxib may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Etoricoxib.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Etoricoxib is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Etoricoxib.Investigational
NeamineEtoricoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe metabolism of Etoricoxib can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Etoricoxib can be decreased when combined with Nelfinavir.Approved
NemonoxacinEtoricoxib may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinEtoricoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etoricoxib.Approved
NetilmicinEtoricoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Etoricoxib can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Etoricoxib can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Etoricoxib can be decreased when combined with Nicardipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etoricoxib.Approved
NilotinibThe metabolism of Etoricoxib can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etoricoxib.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Etoricoxib.Investigational
NorfloxacinEtoricoxib may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinEtoricoxib may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe metabolism of Etoricoxib can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etoricoxib.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etoricoxib.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etoricoxib.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Etoricoxib.Investigational
OmeprazoleThe metabolism of Etoricoxib can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Etoricoxib.Vet Approved
OsimertinibThe serum concentration of Etoricoxib can be increased when it is combined with Osimertinib.Approved
OtamixabanEtoricoxib may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etoricoxib.Approved
OxprenololEtoricoxib may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etoricoxib.Withdrawn
PalbociclibThe serum concentration of Etoricoxib can be increased when it is combined with Palbociclib.Approved
PamidronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pamidronate.Approved
PanobinostatThe serum concentration of Etoricoxib can be increased when it is combined with Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Parecoxib.Approved
ParomomycinEtoricoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineThe metabolism of Etoricoxib can be decreased when combined with Paroxetine.Approved, Investigational
PazufloxacinEtoricoxib may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinEtoricoxib may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Etoricoxib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololEtoricoxib may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Etoricoxib can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateEtoricoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Etoricoxib.Approved
PhenindioneEtoricoxib may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Etoricoxib can be increased when combined with Phenobarbital.Approved
PhenprocoumonEtoricoxib may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Etoricoxib.Approved, Vet Approved
PhenytoinThe metabolism of Etoricoxib can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoricoxib.Approved, Investigational
PindololEtoricoxib may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinEtoricoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideEtoricoxib may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etoricoxib.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etoricoxib.Approved, Investigational
PlicamycinEtoricoxib may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
Polyestradiol phosphateEtoricoxib may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Etoricoxib.Approved
PosaconazoleThe metabolism of Etoricoxib can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololEtoricoxib may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Etoricoxib.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Etoricoxib can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Etoricoxib can be increased when it is combined with Probenecid.Approved
PromazineThe metabolism of Etoricoxib can be decreased when combined with Promazine.Approved, Vet Approved
PromestrieneEtoricoxib may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Etoricoxib.Approved
PropranololEtoricoxib may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Etoricoxib.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Etoricoxib.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Etoricoxib.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Etoricoxib.Vet Approved
Protein CEtoricoxib may increase the anticoagulant activities of Protein C.Approved
Protein S humanEtoricoxib may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEtoricoxib may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinEtoricoxib may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Etoricoxib.Investigational
PuromycinEtoricoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Etoricoxib can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Etoricoxib.Approved, Investigational
QuinestrolEtoricoxib may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etoricoxib.Approved
QuinidineThe metabolism of Etoricoxib can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Etoricoxib can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Etoricoxib.Approved
RanolazineThe metabolism of Etoricoxib can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etoricoxib.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etoricoxib.Experimental, Investigational
ReviparinEtoricoxib may increase the anticoagulant activities of Reviparin.Approved
RibostamycinEtoricoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe metabolism of Etoricoxib can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Etoricoxib can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Etoricoxib can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Risedronate.Approved, Investigational
RitonavirThe metabolism of Etoricoxib can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanEtoricoxib may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Etoricoxib.Investigational, Withdrawn
RolapitantThe metabolism of Etoricoxib can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Etoricoxib can be decreased when combined with Ropinirole.Approved, Investigational
RosoxacinEtoricoxib may increase the neuroexcitatory activities of Rosoxacin.Approved
S EquolEtoricoxib may increase the thrombogenic activities of S Equol.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Etoricoxib.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etoricoxib.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Etoricoxib.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Etoricoxib.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etoricoxib.Experimental
SaquinavirThe metabolism of Etoricoxib can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Etoricoxib.Investigational
SecobarbitalThe metabolism of Etoricoxib can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolEtoricoxib may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etoricoxib.Approved, Investigational
SertralineSertraline may increase the antiplatelet activities of Etoricoxib.Approved
SildenafilThe metabolism of Etoricoxib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Etoricoxib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Etoricoxib can be increased when it is combined with Simeprevir.Approved
SisomicinEtoricoxib may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe metabolism of Etoricoxib can be decreased when combined with Sorafenib.Approved, Investigational
SotalolEtoricoxib may decrease the antihypertensive activities of Sotalol.Approved
SP1049CEtoricoxib may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinEtoricoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinEtoricoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Etoricoxib.Approved
SpironolactoneEtoricoxib may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Etoricoxib.Investigational
St. John's WortThe serum concentration of Etoricoxib can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Etoricoxib can be increased when it is combined with Stiripentol.Approved
StreptomycinEtoricoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinEtoricoxib may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Etoricoxib can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Etoricoxib can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etoricoxib.Approved
SulfisoxazoleThe metabolism of Etoricoxib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Etoricoxib.Approved
SulodexideEtoricoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Etoricoxib.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Etoricoxib.Approved, Withdrawn
Synthetic Conjugated Estrogens, AEtoricoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BEtoricoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusEtoricoxib may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Etoricoxib.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Etoricoxib.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Etoricoxib.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Technetium Tc-99m Medronate.Approved
TelaprevirThe metabolism of Etoricoxib can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Etoricoxib can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etoricoxib.Approved, Investigational
TemafloxacinEtoricoxib may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Etoricoxib.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etoricoxib.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Etoricoxib.Vet Approved
TerbinafineThe metabolism of Etoricoxib can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Etoricoxib can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Etoricoxib can be decreased when combined with Theophylline.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Etoricoxib.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etoricoxib.Approved
TiboloneEtoricoxib may increase the thrombogenic activities of Tibolone.Approved
TicagrelorThe metabolism of Etoricoxib can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Etoricoxib can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tiludronate.Approved, Vet Approved
TimololEtoricoxib may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Etoricoxib.Investigational
TipranavirThe metabolism of Etoricoxib can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tixocortol.Approved
TobramycinEtoricoxib may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Etoricoxib can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Etoricoxib can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Etoricoxib.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etoricoxib.Approved
TorasemideEtoricoxib may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Etoricoxib.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Etoricoxib.Approved, Investigational
TranylcypromineThe metabolism of Etoricoxib can be decreased when combined with Tranylcypromine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etoricoxib.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etoricoxib.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Triamcinolone.Approved, Vet Approved
TriamtereneEtoricoxib may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etoricoxib.Approved, Vet Approved
TrimethoprimThe metabolism of Etoricoxib can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Etoricoxib.Approved
TrovafloxacinEtoricoxib may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Etoricoxib.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etoricoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Etoricoxib can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinEtoricoxib may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Etoricoxib can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Etoricoxib.Approved
VemurafenibThe serum concentration of Etoricoxib can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Etoricoxib.Approved
VerapamilThe metabolism of Etoricoxib can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Etoricoxib can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinEtoricoxib may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEtoricoxib may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Etoricoxib may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Etoricoxib can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etoricoxib.Approved
ZeranolEtoricoxib may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Etoricoxib.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Etoricoxib.Withdrawn
ZiprasidoneThe metabolism of Etoricoxib can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etoricoxib.Withdrawn
ZorubicinEtoricoxib may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Andrea Castellin, Paolo Stabile, Francesco Fontana, Ottorino De Lucchi, Andrea Caporale, Stefano Tartaggia, “PROCESS FOR PREPARING 1-(6-METHYLPYRIDIN-3-YL)-2-[4-(METHYLSULFONYL)PHENYL]ETHANONE, AN INTERMEDIATE OF ETORICOXIB.” U.S. Patent US20120232281, issued September 13, 2012.

US20120232281
General ReferencesNot Available
External Links
ATC CodesM01AH05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9776
Blood Brain Barrier+0.9399
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.845
P-glycoprotein inhibitor INon-inhibitor0.7624
P-glycoprotein inhibitor IINon-inhibitor0.9869
Renal organic cation transporterNon-inhibitor0.8267
CYP450 2C9 substrateNon-substrate0.6702
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.506
CYP450 1A2 substrateInhibitor0.6415
CYP450 2C9 inhibitorInhibitor0.8528
CYP450 2D6 inhibitorNon-inhibitor0.9268
CYP450 2C19 inhibitorInhibitor0.9087
CYP450 3A4 inhibitorInhibitor0.585
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8848
Ames testNon AMES toxic0.7952
CarcinogenicityNon-carcinogens0.6856
BiodegradationNot ready biodegradable0.9961
Rat acute toxicity2.4100 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9934
hERG inhibition (predictor II)Non-inhibitor0.8582
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00328 mg/mLALOGPS
logP3.7ALOGPS
logP2.79ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)19.69ChemAxon
pKa (Strongest Basic)4.96ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area59.92 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity95.04 m3·mol-1ChemAxon
Polarizability36.42 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bipyridines and oligopyridines. These are organic compounds containing two pyridine rings linked to each other.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassBipyridines and oligopyridines
Direct ParentBipyridines and oligopyridines
Alternative Parents
Substituents
  • 3-phenylpyridine
  • Bipyridine
  • Methylpyridine
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Sulfonyl
  • Sulfone
  • Azacycle
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P: Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):85-94. Epub 2006 Jul 3. [PubMed:17164136 ]
  4. FitzGerald GA: COX-2 in play at the AHA and the FDA. Trends Pharmacol Sci. 2007 Jul;28(7):303-7. Epub 2007 Jun 18. [PubMed:17573128 ]
  5. Yuan Y, Hunt RH: Global gastrointestinal safety profile of etoricoxib and lumiracoxib. Curr Pharm Des. 2007;13(22):2237-47. [PubMed:17691997 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM: Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703-20. [PubMed:18840026 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on August 30, 2007 09:49 / Updated on August 17, 2016 12:23